This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Belcaro, G. Articles by Acerbi, G. Search for Related Content PubMed PubMed Citation Articles by Belcaro, G. Articles by Acerbi, G. Social Bookmarking                         What's this?

HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in Chronic Venous Disease and Microangiopathy: An Independent Prospective, Controlled, Randomized Trial

Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy; Irvine Vascular Laboratory, St Mary's Hospital, Imperial College, Vascular Unit, Ealing Hospital, London; Via Vespucci 65, 65100 Pescara, Italy

M. R. Cesarone, MD

P. Bavera, MD

A. Ricci, MD

S. Renton, MD

M. Leon, MD

E. Ippolito, MD

M. Dugall, MD

G. Acerbi, MD

Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy; Irvine Vascular Laboratory, St Mary's Hospital, Imperial College, Vascular Unit, Ealing Hospital, London

Objectives: The aim of this study was to demonstrate whether and how HR (Venoruton¹⁰⁰⁰, Paroven, 0-[beta-hydroxyethyl]-rutosides) and Daflon (diosmin, 500 mg) were comparatively effective in improving the microcirculation in venous hypertension and microangiopathy.

Methods: A group of 90 patients with severe venous hypertension due to chronic venous insufficiency, ankle swelling, and lipodermatosclerosis were included. After informed consent, patients were randomized into a Venoruton and a Daflon (DF) group: patients in the Venoruton group received oral HR (2 g/day for 8 weeks); those in the Daflon group received three 500-mg tablets daily every 8 hours. The two groups were comparable for age and sex distribution. The mean age was 41 years (SD ± 11) in the Venoruton group (46 patients) and 41.3 (SD ± 12) in the DF group (44 patients).

Results: There were no differences in microcirculatory parameters between the Venoruton and DF treatment groups at inclusion. There was no significant change between inclusion and measurements at 8 weeks in the DF group. In comparison, a significant decrease (P < .05) in RF (resting skin flux) and RAS (rate of ankle swelling) was observed in the Venoruton group (P < .00 1). The decrease in capillary filtration was associated with improvement in signs and symptoms (measured by an analogue scale line) (P < .05). Symptomatic improvement was clinically and statistically significant and important only in the Venoruton group. No side effects and no drop-outs were observed.

Conclusion: Venous microangiopathy was improved by the treatment with Venoruton. The comparison with Daflon indicates that HR is comparatively more effective both on microcirculatory parameters and on signs and symptoms.

Key Words: venous disease • varicose veins • ulcerations • HR • Paroven • Venoruton 0-(beta-hydroxyethyl)-rutosides) • elastic compression • edema • veins • venous microangiopathy

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 7, No. 3, 139-145 (2002)
DOI: 10.1177/107424840200700303


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, G. Vinciguerra, A. Ricci, G. Gizzi, E. Ippolito, F. Fano, M. Dugall, et al. Circulating Endothelial Cells in Venous Blood as a Marker of Endothelial Damage in Chronic Venous Insufficiency: Improvement with Venoruton Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 93 - 99. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, G. Vinciguerra, A. Ricci, A. Di Renzo, I. Ruffini, G. Gizzi, E. Ippolito, et al. Venoruton(R) vs Daflon(R): Evaluation of Effects on Quality of Life in Chronic Venous Insufficiency Angiology, March 1, 2006; 57(2): 131 - 138. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, G. Vinciguerra, A. Ricci, G. Gizzi, E. Ippolito, F. Fano, M. Dugall, et al. HR, 0-(Beta-Hydroxyethyl)-Rutosides; (Venoruton(R)): Rapid Relief of Signs/Symptoms in Chronic Venous Insufficiency and Microangiopathy: A Prospective, Controlled Study Angiology, March 1, 2005; 56(2): 165 - 172. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, A. Di Renzo, G. Vinciguerra, A. Ricci, G. Gizzi, E. Ippolito, F. Fano, et al. HR, 0-(Beta-Hydroxyethyl)-Rutosides, in Comparison with Diosmin+Hesperidin in Chronic Venous Insufficiency and Venous Microangiopathy: An Independent, Prospective, Comparative Registry Study Angiology, January 1, 2005; 56(1): 1 - 8. [Abstract] [PDF]